The orphan receptor tyrosine kinase ErbB2 (also known as HER2 or Neu) transforms cells when overexpressed 1 , and it is an important therapeutic target in human cancer 2, 3 . Structural studies 4, 5 have suggested that the oncogenic (and ligand-independent) signalling properties of ErbB2 result from the absence of a key intramolecular 'tether' in the extracellular region that autoinhibits other human ErbB receptors, including the epidermal growth factor (EGF) receptor 6 . Although ErbB2 is unique among the four human ErbB receptors 6, 7 , here we show that it is the closest structural relative of the single EGF receptor family member in Drosophila melanogaster (dEGFR). Genetic and biochemical data show that dEGFR is tightly regulated by growth factor ligands 8 , yet a crystal structure shows that it, too, lacks the intramolecular tether seen in human EGFR, ErbB3 and ErbB4. Instead, a distinct set of autoinhibitory interdomain interactions hold unliganded dEGFR in an inactive state. All of these interactions are maintained (and even extended) in ErbB2, arguing against the suggestion that ErbB2 lacks autoinhibition. We therefore suggest that normal and pathogenic ErbB2 signalling may be regulated by ligands in the same way as dEGFR. Our findings have important implications for ErbB2 regulation in human cancer, and for developing therapeutic approaches that target novel aspects of this orphan receptor.
Ligand-induced activation of EGFR involves a marked change in the extracellular region from a 'tethered' (inactive) to an 'extended' (active) configuration 9 ( Fig. 1a) in which an exposed 'dimerization arm' in domain II drives the formation of receptor dimers 10, 11 . In tethered EGFR, the dimerization arm is occluded by autoinhibitory intramolecular interactions between domains II and IV, which are also seen in unliganded ErbB3 and ErbB4-but are absent in ErbB2 (refs 6, 12) . ErbB2 is structurally unique. Even without a bound ligand its extracellular region resembles the extended (EGF-bound) form of EGFR (Fig. 1b, c) , with the dimerization arm exposed and apparently 'poised' to drive receptor-receptor interactions 4, 5 . No known soluble ligand directly regulates ErbB2, and it is the only family member that transforms cells when simply overexpressed (without ligand addition) 1 . Thus, ErbB2 is regarded as an 'auto-activated' receptor that adopts a constitutively activated configuration that can form signalling-active heterodimers (or homodimers) without direct regulation by a growth factor. These properties are thought to explain how ErbB2 overexpression causes cancer 7 . Although ErbB2 is viewed as an oddity among human ErbB receptors, we show here that it is the closest structural relative of the single EGF receptor family member of D. melanogaster (dEGFR). Moreover, the structural features that initially suggested constitutive activation of ErbB2 seem important for dEGFR autoinhibition. Thus, ErbB2 shares more similarities with a possible ancestral EGF receptor than does human EGFR itself.
We determined the 2.7-Å X-ray crystal structure of the unliganded dEGFR extracellular region, encompassing domains I to IV (Supplementary Table 1 ). D. melanogaster contains a single EGFR/ ErbB-receptor, which is tightly regulated by four different ligands (Spitz, Gurken, Keren and Vein) in distinct developmental contexts 8 . Ligand binding is required for dEGFR activation in cultured cells 13, 14 and for strong dimerization of its isolated extracellular region in vitro 13 . Sequence analyses indicate that the overall domain arrangement in dEGFR is the same as in human ErbB receptors, except for an extra cysteine-rich domain (domain V, which is predicted to be similar to domains II and IV) at the carboxy terminus of the invertebrate EGFR extracellular region. Over domains I-IV (about 620 amino-acid residues long), dEGFR shares 39% sequence identity with human EGFR (hEGFR) and 35% with human ErbB2 ( Supplementary  Fig. 1 ). Because it is tightly regulated by ligands, we expected that an unliganded form of the dEGFR extracellular region (s-dEGFR) would adopt a tethered configuration similar to that seen in Fig. 1a for hEGFR. Instead, we found that s-dEGFR encompassing domains I-IV (s-dEGFRDV) is fully extended even in the absence of ligand (Fig. 1d) , and closely resembles sErbB2 (Fig. 1c) . The s-dEGFRDV dimerization arm is exposed, and the ligand-binding sites on domains I and III are in direct contact (Fig. 1d) . A structural overlay of sErbB2 and s-dEGFRDV (Fig. 2a) shows them to be remarkably similar. Thus, the same configuration is seen for the inactive state of one ErbB receptor extracellular region (s-dEGFRDV without ligand) and another that is thought to be constitutively active (sErbB2).
Small-angle X-ray scattering (SAXS) studies excluded the possibility that crystal packing causes s-dEGFRDV to be extended. SAXS measurements of the maximum molecular dimension (D max ), together with low-resolution molecular envelopes, allow clear distinction between extended and tethered configurations of ErbB receptor extracellular regions in solution 15 . D max for s-dEGFRDV in solution is 130 Å (Supplementary Table 2 ), equal to the value measured for sErbB2 (ref. 15 ) and 25-30 Å larger than values for the tethered human EGFR extracellular region (about 105 Å ) 15 . Low-resolution molecular envelopes (Fig. 2b ) also show that s-dEGFRDV is extended in solution. SAXS studies of complete s-dEGFR (with domain V) gave an average D max of 165 Å (Supplementary Table 2 ), indicating that domain V simply projects from the end of domain IV to extend the structure ( Fig. 2b and Supplementary Fig. 2 ). Mutational studies provide further evidence for the absence of an autoinhibitory tether in dEGFR. The affinity of human EGFR for its ligands is increased when the domain II/IV tether is weakened with mutations or abolished by removing domain IV 16, 17 ( Supplementary Fig. 3a ). These mutations favour EGF binding by reducing the work required to relocate domains I and III for interaction with the same EGF molecule (and do not cause constitutive hEGFR activation 16, 18, 19 ). Equivalent substitutions or deletions in s-dEGFR do not enhance Spitz binding ( Supplementary  Fig. 3b ), indicating that dEGFR has no equivalent domain II/IV tether. Thus, our crystallographic and solution studies show that the unactivated Drosophila EGFR extracellular region adopts the same extended configuration as that seen for ErbB2.
Key elements of unliganded s-dEGFR overlay very well on the unactivated human EGFR extracellular region (s-hEGFR). As shown in Fig. 3a , the conformation of domain II in inactive s-dEGFRDV (red) closely resembles that of domain II in inactive (tethered) s-hEGFR (grey) in an overlay using domain I as reference. This seems to be a characteristic 'inactive' domain II conformation, which is also shared by the unliganded ErbB3 and ErbB4 extracellular regions 12, 20 . By contrast, activated s-hEGFR 11 has a strikingly different domain II structure, with a roughly 12u bend between modules m4 and m5 (at the green arrow in Fig. 3b ) that is known to be crucial for ligandinduced dimerization 16 . The domain II conformation in sErbB2 superimposes precisely on the inactive s-dEGFR and s-hEGFR structures (cyan structure in Fig. 3a ), but not on the activated human EGFR structure. ErbB2 therefore has an 'inactive-like' domain II, indicating that published sErbB2 structures 4, 5 may represent an inactive (autoinhibited) configuration.
The failure of sErbB2 and unliganded s-dEGFRDV to self-associate strongly, despite both having an exposed dimerization arm, also suggests an 'inactive', or dimerization-incompetent domain II conformation. The ErbB2 extracellular region does not homodimerize in solution 21, 22 or in crystals 4, 5 , and its heterodimerization with other sErbB proteins is barely detectable 21, 22 . Unliganded s-dEGFRDV forms a crystallographic dimer mediated almost entirely by dimerization arm contacts ( Supplementary Fig. 4 ). This self-association occurs only weakly in solution, with an approximate K d of 40 mM as determined by analytical ultracentrifugation experiments ( Supplementary Fig. 4 ). Strong dimerization of s-dEGFRDV or s-dEGFR requires Spitz binding ( Supplementary Fig. 4a ). Thus, the extracellular region of ErbB2-the human ErbB receptor believed to be unique in its ability to form ligand-independent homodimers and heterodimers 7, 23 -has less propensity for self-association than the equivalent region of the unliganded Drosophila EGF receptor. ErbB2 also shows no greater tendency than unliganded hEGFR to homodimerize in cells 24 , and it is not constitutively active when expressed at physiologically relevant levels in insect cells 25 . Together, these data point to ErbB2 being an inactive receptor-and one that may be more stringently autoinhibited than dEGFR. Figure 3 suggests a mechanism for dEGFR regulation by growth factor binding that may also be relevant for ErbB2. Wedging an EGFlike molecule between the two ligand-binding domains I and III will push them apart as shown in Fig. 3c , necessitating a significant bend in domain II (which links domains I and III). Movement of disulphidebonded module m5 with respect to m4 (at the green arrow in Fig. 3b ) accounts for most of this bend, and effectively links ligand binding to reorientation of the dimerization arm. The result is a bent domain II conformation that can present a self-complementary dimerization interface (for homodimerization) or one that is optimized for heterodimerization. Direct interactions between domains I and III of s-dEGFR work against this process, and are therefore autoinhibitory. Interactions between domains I and III of s-dEGFRDV involve regions that correspond exactly to the ligand-binding sites of hEGFR 10, 11 , and they therefore directly occlude the ligand-binding sites (Fig. 1a) burying 452 Å 2 of surface. Details of these interactions are shown in Supplementary Fig. 5a . The same elements in sErbB2 also contribute Binding of EGF (magenta) to domains I and III stabilizes extended s-hEGFR, exposing the dimerization arm (centre) to promote receptor dimerization (right) 9 . Most of domain IV was missing from extended s-hEGFR 10, 11 structures and was added to the centre and right-hand panels using the domain IV structure of tethered s-hEGFR (left) 17 . b, Surface representation of a monomer from the EGF-bound s-hEGFR dimer (PDB accession 1ivo) 11 . c, sErbB2 (PDB accession 1n8z, shown in surface representation) adopts an extended configuration similar to that of an activated s-hEGFR monomer 4 . d, Even in its inactive, unliganded state, s-dEGFRDV is completely extended and closely resembles both sErbB2 and activated s-hEGFR.
to direct interactions between domains I and III 4, 5 but are augmented by additional contacts to bring domains I and III even closer together (by about 8 Å ) than in s-dEGFR (Fig. 2a) , burying a total surface of about 1,250 Å 2 ( Supplementary Fig. 5b ). The direct interactions between domains I and III seen in dEGFR (and ErbB2) are autoinhibitory because they force the two parts of the ligand-binding site so close to one another that ligand cannot be accommodated. By contrast, the domain II/IV tether in hEGFR (Fig. 1a) pulls the two halves of the ligand-binding site (on domains I and III) too far apart for them both to contact the same ligand molecule simultaneously. The autoinhibitory consequence for ligand binding is similar in both cases, with work being required to separate domains I and III in dEGFR but (conversely) to draw them together in hEGFR by breaking the domain II/IV tether. Thus, these are variations on the same autoinhibitory theme.
The close apposition of domains I and III in dEGFR also promotes an important set of interactions between domains I and II (Fig. 3c ) that stabilize the inactive domain II conformation. Side chains from the 'back' of s-dEGFR domain II in modules m5 and m6 (Y259 and H270, respectively) pack against a hydrophobic patch on domain I comprising the side chains of I2, I4 and Y32 (Fig. 3c and Supplementary Fig. 6a ) and form hydrogen bonds with D34 in domain I. These interactions restrain the orientation of modules m5 and m6 with respect to m4 and maintain the dimerization arm in the 'inactive' position shown in Fig. 3a , c. Very similar sets of interactions between domains I and II occur in sErbB2 ( Supplementary Fig. 6b ), in inactive hEGFR ( Supplementary Fig. 6c ), and also in unliganded ErbB3 and ErbB4 (refs 12, 20) . All of these interactions are broken in the active configuration ( Fig. 3d and Supplementary Fig. 6d ), so that domain II modules m5 and m6 no longer make direct contact with domain I, and the dimerization arm becomes reoriented. Disrupting these interactions between domains I and II in s-dEGFR, by mutation of Y259 and H270 to alanine and serine, respectively, enhances Spitz binding to about the same extent as domain II/IV tether mutations enhance EGF binding to s-hEGFR 17 ( Supplementary Fig. 7 and Supplementary Table 3 ). From the perspective of ligand binding, domain I/II contacts in dEGFR therefore constitute an (autoinhibitory) energetic barrier that is similar in strength to the domain II/IV tether in human EGFR, ErbB3 and ErbB4. Disrupting domain I/II contacts in intact dEGFR or ErbB2 did not elevate the constitutive activity of these receptors (data not shown), but neither does disruption of domain II/IV tether contacts in hEGFR 16, 18, 19 . Breaking autoinhibitory interactions in the extracellular region, although necessary for activation, is clearly not sufficient. Indeed, even if domain IV is deleted entirely from s-hEGFR (so that the tether cannot form), dimerization still requires EGF addition 10 . Thus, the unliganded Drosophila and human EGF receptors rely on different sets of autoinhibitory intramolecular interactions to oppose ligand binding and dimerization.
The fact that ErbB2 maintains-and even extends-all of the autoinhibitory interactions seen in Drosophila EGFR militates against the prevailing notion that ErbB2 is 'poised' to dimerize through its exposed dimerization arm 4, 5 . Furthermore, the failure of sErbB2 to form homodimers or heterodimers in vitro 21, 22 suggests that it is even more stringently autoinhibited than s-dEGFR (which does homodimerize weakly)-which is consistent with its larger domain I/III interface ( Supplementary Fig. 5 ). Nonetheless, crosslinking and coimmunoprecipitation studies show that intact ErbB2 can form homodimers and heterodimers in mammalian cells 7, 23, 26 . One possible explanation is that ErbB2 relies uniquely on interactions outside its extracellular region to drive dimerization. A second possibility is that unknown cellular ligands promote ErbB2 activation when it is overexpressed in mammalian cells (but not in insect cells 25 ). The first of these possibilities is countered by reports that deletion of the cytoplasmic region does not abolish ErbB2 homodimerization or heterodimerization 26 -although a key role for the transmembrane domain cannot be excluded. The second possibility seems unlikely, given the failure of substantial efforts in the 1980s and 1990s to identify soluble ligands that directly activate ErbB2 (ref. 7) .
Although no genuine soluble ligand for ErbB2 is known, at least one membrane-bound regulator that contains EGF-like domains has been identified 27 . A subunit of Muc4 (ASGP2) was reported to interact with ErbB2 and promote its tyrosine phosphorylation. An EGFlike domain in membrane-associated Muc4 might bind between domains I and III of ErbB2 and induce conformational changes of Table 2 ). The s-dEGFRDV envelope readily accommodates the crystallographic model. In intact s-dEGFR, domain V (orange) seems simply to add to the maximum dimension. Domain V and the C terminus of domain IV (poorly defined in our crystal structure) were modelled with s-hEGFR domain IV as template. In the right-hand panel, the three most C-terminal terminal disulphide-linked modules of domain V have been removed. The fact that these are not accommodated by the SAXS envelope suggests flexibility at the C terminus.
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LETTERS the sort depicted in Fig. 3c, d to promote the ability of ErbB2 to form homodimers and/or heterodimers. Similarly, it has been shown genetically in Drosophila that Spitz must be palmitoylated (which drives its membrane association 28 ) to regulate dEGFR in vivo 28 . Gurken and Keren have a similar palmitoylation site, whereas Vein-considered to be a 'weak' dEGFR ligand 8 -does not. Thus, membrane association seems to be a key feature of ligands (Muc4 and Spitz) that activate the two ErbB receptors known to adopt an extended configuration in the absence of ligand (ErbB2 and dEGFR). Membrane association may be required to increase the local ligand concentration at the cell surface, so as to promote the ligand's ability to 'wedge apart' domains I and III of dEGFR or ErbB2 (breaking autoinhibitory interactions between domains I and III). By contrast, the tethered configuration of hEGFR, ErbB3 and ErbB4 (Fig. 1a) keeps the ligand-binding sites on domains I and III fully exposed and freely accessible to soluble growth factors. We speculate that evolution of the domain II/IV tether as a distinct mode of autoinhibition might have occurred alongside the emergence of the ability of ErbB receptors (other than ErbB2) to respond to soluble (rather than membrane-bound) growth factor ligands.
Given the importance of ErbB2 in human cancer, and its validated utility as a target of cancer therapeutics 3 , the view of ErbB2 regulation presented here has several implications. The development of agents that stabilize autoinhibitory interactions might represent a new therapeutic avenue for inhibiting ErbB2 signalling in cancer. Equally, the fact that ErbB2 shows such striking resemblance to a tightly ligand-regulated invertebrate EGF receptor suggests that ErbB2 also has activating ligands. Identifying these probably membraneassociated ligands, and understanding their role in activating ErbB2 in different human cancers, should provide new directions for therapeutic targeting of ErbB receptor signalling.
METHODS SUMMARY
Histidine-tagged s-dEGFR and s-dEGFRDV were produced by secretion from baculovirus-infected Spodoptera frugiperda Sf9 cells or transfected Drosophila S2 cells. The C-terminal amino acid of s-dEGFRDV was T589 in the numbering convention used in Supplementary Fig. 1 (see Methods). Secreted protein was collected by metal-affinity chromatography and further purified by ionexchange and size-exclusion chromatography as described 13 . Surface plasmon resonance (SPR), SAXS and sedimentation equilibrium analytical ultracentrifugation studies were performed essentially as described 13, 15, 16 . Purified s-dEGFRDV was crystallized using the vapour diffusion method in 10% PEG 4000, 5% Jeffamine M-600, pH 7.0, 12.5% ethylene glycol, 100 mM HEPES, pH 7.4, 50 mM KCl. Plate-shaped crystals of approximate dimensions 200 mm 3 200 mm 3 75 mm grew in 1-5 days and were frozen directly from the mother liquor. Data were collected using beamline 23ID-D at the Advanced Photon Source (Argonne, Illinois) as described in Supplementary Table 1 . The structure of s-dEGFRDV was solved using molecular replacement (MR) methods. Search models based on the coordinates of domains I and III from ErbB2 (PDB accession 2a91) 5 were generated by replacing non-conserved amino acids with alanines. Although MR solutions could not be found for domains II or IV, initial maps calculated using phases from models containing only domains I and III showed strong density for domain II. Model building with COOT 29 was alternated with successive rounds of restrained refinement using REFMAC 30 . In Fig. 6 ).
In EGF-bound s-hEGFR (d), the side chains shown in green space-filling representation no longer interact, and domain II is bent.
later stages of refinement, composite omit maps were generated, which allowed much of domain IV to be built and oligosaccharides to be placed.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Protein expression and purification. Coding regions for wild-type and mutated forms of s-dEGFR were subcloned into pFastbac-1 and pMT/V5-His A (Invitrogen) for expression in Spodoptera frugiperda (Sf9) and Drosophila melanogaster Schneider-2 (S2) cells respectively. A C-terminal hexahistidine tag was incorporated into all constructs by PCR. s-dEGFRDV ended at T589 using the numbering scheme employed in Supplementary Fig. 1 (see the comments in Crystallography section below on dEGFR numbering), and s-dEGFRDIV-V was truncated at N493. Two sets of mutations were made to disrupt the domain I/II autoinhibitory interface for Supplementary Fig. 7 and Supplementary Table 3 . In one, Y259 and H270 in domain II were mutated to alanine and serine, respectively. In the second, sites in domains I and II were mutated to give the tetramutant I2A/Y32A/Y259A/H270S. The effects of these mutations were assessed both in the background of wild-type s-dEGFR and a Y242S/Y247S mutant in which dimer contacts had been disrupted. The s-dEGFRDV dim-arm construct referred to in Supplementary Fig. 4 and Supplementary Table 2 contains a series of mutations in the domain II dimerization arm analogous to those previously shown to abolish ligand-induced dimerization of human sEGFR 10 : Y242E, N243A, T245D, Y247E, V248A and L249D. The s-dEGFR tether mutant referred to in Supplementary Fig. 3 contains three mutations in domain IV analogous to those that break all intramolecular hydrogenbonding interactions between domains II and IV observed in the unliganded s-hEGFR structure 17 : D547A, H550A and K559A. All mutations were generated with the QuikChange mutagenesis kit (Stratagene) and fully sequenced.
Stable S2 cell pools and recombinant baculoviruses were generated as described 13, 17, 31 , and each protein of interest was secreted into the culture medium. For S2 cell-expressed proteins, S2 cells were grown in EX-CELL 420 serum-free medium (Sigma-Aldrich) to a density of about (5-10) 3 10 6 cells ml
21
, and protein expression was induced with 500 mM CuSO 4 for 3-4 days. For Sf9 cellexpressed proteins, Sf9 cells were grown in Sf900II medium (Invitrogen-Gibco) to a density of (2-3) 3 10 6 cells ml 21 and were infected with recombinant baculovirus for 3-4 days. In each case, 2-4 l of conditioned medium were flowed over a 3-4-ml bed volume of Ni 21 -nitrilotriacetate agarose (Qiagen). After the column had been washed with 25 mM MES, pH 6.0, 150 mM NaCl (buffer A), bound proteins were eluted with increasing concentrations of imidazole in buffer A. Protein-containing fractions were applied to a Uno-S (Bio-Rad) cation-exchange column equilibrated in buffer A, and were eluted with a salt gradient from 150 mM to 1 M NaCl in buffer A. s-dEGFR proteins were eluted between 200 and 500 mM NaCl and were concentrated with a Centricon-50 concentrator (Millipore) before further purification by size-exclusion chromatography with a Superose-6 column (GE Healthcare) equilibrated in buffer B (25 mM HEPES, pH 8.0, 150 mM NaCl). Secreted Spitz and Spitz C29S were purified from S2 cells exactly as described previously 13, 28, 31 . Surface plasmon resonance (SPR). Secreted Spitz was immobilized on CM5 sensorchips by using amine coupling, exactly as described previously 13 . Increasing concentrations of s-dEGFR proteins (12.5-6,400 nM) were then flowed over the sensorchip in buffer B at 25 uC. The sensorchip surface was regenerated after each injection with the use of 10 mM sodium acetate, pH 4.5, 1 M NaCl, as described 13 . The maximum SPR response at steady state for each s-dEGFR concentration was plotted against s-dEGFR concentration, and the resulting curves could be fitted straightforwardly to simple binding isotherms with the program Prism (GraphPad), from which apparent K d values were obtained. Standard error of the mean values were generated from at least three independent measurements, using at least two independent preparations of each protein. SAXS. SAXS data were collected at 25 uC with a rotating anode source at Fox Chase Cancer Center, as described 15 , or at CHESS beamline G1, using protein samples at concentrations between 1 and 6 mg ml 21 in buffer B. Data handling and reduction were performed as described previously 15 or with the program Datasqueeze (Datasqueeze Software). Potential problems with radiation-induced denaturation were monitored by inspection of Kratky plots with increasing exposure time, graphing IQ 2 as a function of Q, where I is the scattered intensity and Q 5 4psin(h/2)/l (where Q is the magnitude of the scattering vector, h the scattering angle and l the X-ray wavelength). The program GNOM 32 was used to obtain P(r) curves, the maximum dimension of the molecule (D max ) and its radius of gyration (R g ). Quoted R g values (Supplementary Table 2 ) represent means (and standard deviations) from at least three independent determinations. D max values were determined empirically by recomputing P(r) curves in GNOM with a series of different r max values (in steps of 5 Å ), and selecting as D max the r max value at which P(r) most closely approached zero while giving a plausible P(r) curve. Errors in D max values are quoted as 65 Å on the basis of the empirical approach used for their determination. Low-resolution molecular envelopes were generated ab initio with the program DAMMIN as described previously 15, 33 , using SAXS data collected on the home source with s-dEGFR concentrations lower than 1 mg ml 21 . In brief, ten iterations of DAMMIN were averaged and filtered as described 34 , using the DAMAVER suite of programs. Crystal structures of models were docked into the resulting 'most probable' envelopes with SITUS 35 , and the outputs were displayed and manually refined with the UCSF Chimera package (http:// www.cgl.ucsf.edu/chimera) 36 . Sedimentation equilibrium ultracentrifugation. Experiments were performed exactly as described 21 , with the following modifications. Receptor extracellular regions at 2, 4 and 8 mM, both with and without a 1.2-fold excess of Spitz, were centrifuged in buffer B at 6,000, 9,000 and 12,000 r.p.m. in an Optima XL-A analytical ultracentrifuge (Beckman) at 20 uC, using absorbance at 280 nm to detect protein distribution. The program Winmatch (http://www.biotech.uconn. edu/auf/) was used to ensure that samples had reached equilibrium. Data were analysed with Sedfit and Sedphat (http://www.analyticalultracentrifugation.com) and were fitted to a monomer-dimer equilibrium model as described 16 , considering s-dEGFR or the s-dEGFR-Spitz complex as the dimerizing species. Fits used to determine the quoted K d values gave good residuals, with no systematic deviations. In Supplementary Fig. 4a , sedimentation data are plotted as lnA 280 against (r 2 2 r 0 2 /2), where r is the radial position in the sample and r 0 is the radial position of the meniscus. For a single species this representation gives a straight line with a slope proportional to its molecular mass. Standard deviations quoted represent data from at least three independent experiments. Crystallography. Generation of s-dEGFRDV protein suitable for crystallization. The torpedo locus in Drosophila melanogaster encodes two splice variants named dEGFR1 and dEGFR2 that differ only at their N termini 37, 38 . Mature dEGFR1 and dEGFR2 have N-terminal extensions of 21 and 71 amino acids, respectively, which show no significant sequence similarity, are devoid of significant predicted secondary structure and are proteolytically labile as determined by N-terminal sequencing of the corresponding s-dEGFR species. We found that s-dEGFR1 and s-dEGFR2 bind Spitz with the same affinity (data not shown) and that removal of the N-terminal extensions has no influence on Spitz binding (data not shown). Beyond amino acid 22 of mature dEGFR1 (C53 of predicted pro-dEGFR1) and amino acid 72 of mature dEGFR2 (C102 of pro-dEGFR2), the two splice forms are identical. Therefore, to generate a protein amenable to crystallization (s-dEGFR), we deleted amino acids 1-21 and 1-71 of mature dEGFR1 and dEGFR2, respectively (equivalent to amino acids 1-52 and 1-101 of the respective pro forms), so that the N-terminal amino acid of mature s-dEGFR corresponds to K20 of mature dEGFR1 or K70 of mature dEGFR2 (the second residue-V21 in mature dEGFR1 and I71 in mature dEGFR2-is I2 in mature s-dEGFR; Supplementary Fig. 1 ). Immediately before K1 of s-dEGFR, we added a BiP signal sequence (substituted for the native one) to drive the secretion of s-dEGFR into the culture medium, followed by a hexahistidine tag (in addition to the His 6 tag at the C terminus), so that the presumed mature s-dEGFR protein secreted from S2 or Sf9 cells starts with six histidines, which we number 25 to 0. Domain V was also deleted from s-dEGFR at T589 (using the numbering in Supplementary Fig. 1) , yielding s-dEGFRDV, which also has a C-terminal hexahistidine tag. Whereas crystals grown with s-dEGFR2 protein diffracted poorly, s-dEGFRDV crystals diffracted well to 2.7 Å resolution.
Crystallization and data collection. Purified s-dEGFRDV (see above) at 100 mM was crystallized with the vapour diffusion method by mixing equal volumes of protein with a solution containing 10% PEG 4000, 5% Jeffamine M-600, pH 7.0, 12.5% ethylene glycol, 100 mM HEPES, pH 7.4, 50 mM KCl, and equilibrating the mixture over a reservoir of this solution at 21 uC. , giving a solvent content of 62.2%. Molecular replacement and refinement. The structure of s-dEGFRDV was solved with MR methods. Search models based on the coordinates of domains I and III from ErbB2 (PDB accession 2a91) 5 were generated by replacing nonconserved amino acids with alanines. Domains I and III were found in simultaneous but independent searches by using PHASER (CCP4) 30 . Although we were unable to find MR solutions for domains II or IV with a variety of search models, initial maps based on domain I/III models showed strong density for domain II. Model building with COOT 29 was alternated with successive rounds of restrained refinement with REFMAC 30 and solvent flattening with DM 30 . In later stages of refinement, composite omit maps were generated in CNS 40 , which allowed much of domain IV to be built and oligosaccharides to be placed. The final stages of refinement employed TLS refinement 41 with anisotropic motion tensors refined for each of the four domains, using REFMAC 30 . Calculations and figure preparation. Calculations of buried surface were performed with AREAIMOL in the CCP4 suite of programs 30 . Calculations of surface complementarity, S c (ref. 42) , used the program SC in CCP4 (ref. 30 ).
